Andrew Green

List of Publications by Year in Descending Order

335 papers	21,256 citations	60 h-index	138 g-index
351 ext. papers	25,385 ext. citations	6.8 avg, IF	6.38 L-index

#	Paper	IF	Citations
335	Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.. *Breast Cancer Research and Treatment*, **2022**, 192, 529	4.4	1
334	The combination phenotype of B-cell specific Moloney murine leukaemia virus integration site 1 (BMI1) and CD44+/CD24low associates with poor clinicopathological features in African patients with breast cancer. *Gene Reports*, **2022**, 26, 101475	1.4	
333	Standardization of the tumor-stroma ratio scoring method for breast cancer research.. *Breast Cancer Research and Treatment*, **2022**, 193, 545	4.4	2
332	Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion.. *American Journal of Cancer Research*, **2022**, 12, 469-489	4.4	
331	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. *Npj Breast Cancer*, **2022**, 8, 57	7.8	1
330	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.. *Pathobiology*, **2022**, 1-11	3.6	1
329	Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. *Npj Breast Cancer*, **2021**, 7, 143	7.8	1
328	Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. *Breast Cancer Research and Treatment*, **2021**, 1	4.4	0
327	Genome-Wide Analysis Unveils DNA Helicase RECQ1 as a Regulator of Estrogen Response Pathway in Breast Cancer Cells. *Molecular and Cellular Biology*, **2021**, 41,	4.8	1
326	Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. *Biomedicines*, **2021**, 9,	4.8	6
325	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. *Breast Cancer Research*, **2021**, 23, 42	8.3	3
324	The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population. *Annals of Diagnostic Pathology*, **2021**, 51, 151696	2.2	3
323	PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 5015-5024	5.6	1
322	The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. *Breast Cancer Research and Treatment*, **2021**, 188, 53-63	4.4	0
321	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 317-331	4.4	1
320	Werner Syndrome Protein Expression in Breast Cancer. *Clinical Breast Cancer*, **2021**, 21, 57-73.e7	3	3
319	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. *British Journal of Cancer*, **2021**, 124, 494-505	8.7	13

318	The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 293-305	4.4	11
317	Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 615-627	4.4	6
316	The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. *Cancers*, **2021**, 13,	6.6	3
315	Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 621-630	4.4	1
314	The frequency and clinical significance of DNA polymerase beta (POLB) expression in breast ductal carcinoma in situ (DCIS). *Breast Cancer Research and Treatment*, **2021**, 190, 39-51	4.4	
313	A review of the racial heterogeneity of breast cancer stem cells. *Gene*, **2021**, 796-797, 145805	3.8	2
312	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. *Nature Communications*, **2021**, 12, 5406	17.4	6
311	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 181, 541-551	4.4	6
310	Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 6263-6271	5.6	4
309	The prognostic significance of ALDH1A1 expression in early invasive breast cancer. *Histopathology*, **2020**, 77, 437-448	7.3	10
308	A novel prognostic two-gene signature for triple negative breast cancer. *Modern Pathology*, **2020**, 33, 2208-2220	9.8	13
307	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. *BMC Cancer*, **2020**, 20, 425	4.8	5
306	The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. *Breast Cancer Research and Treatment*, **2020**, 182, 581-589	4.4	5
305	SPAG5: An Emerging Oncogene. *Trends in Cancer*, **2020**, 6, 543-547	12.5	9
304	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. *Cancers*, **2020**, 12,	6.6	3
303	Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 402	5.7	29
302	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. *British Journal of Cancer*, **2020**, 122, 1496-1506	8.7	15
301	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. *Npj Breast Cancer*, **2020**, 6, 9	7.8	13

300	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 181, 1-12	4.4	3
299	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. *Cancers*, **2020**, 12,	6.6	2
298	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
297	Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. *Pathobiology*, **2020**, 87, 218-231	3.6	8
296	Visual histological assessment of morphological features reflects the underlying molecular profile in invasive breast cancer: a morphomolecular study. *Histopathology*, **2020**, 77, 631-645	7.3	4
295	A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma. *Clinical Cancer Research*, **2020**, 26, 2898-2907	12.9	4
294	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. *Scientific Reports*, **2020**, 10, 3009	4.9	11
293	PIK3C□expression by fibroblasts promotes triple-negative breast cancer progression. *Journal of Clinical Investigation*, **2020**, 130, 3188-3204	15.9	13
292	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920974201	5.4	3
291	The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. *Cancers*, **2020**, 13,	6.6	3
290	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. *Breast Cancer Research and Treatment*, **2020**, 182, 267-282	4.4	12
289	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 557-564	4.4	5
288	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 349-357	4.4	14
287	Prognostic significance of nucleolar assessment in invasive breast cancer. *Histopathology*, **2020**, 76, 671-684	7.3	7
286	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. *British Journal of Cancer*, **2020**, 122, 94-101	8.7	13
285	Attention by Selection: A Deep Selective Attention Approach to Breast Cancer Classification. *IEEE Transactions on Medical Imaging*, **2020**, 39, 1930-1941	11.7	12
284	The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. *International Journal of Cancer*, **2020**, 146, 2296-2304	7.5	18
283	Breast cancer stem cells: A fallow research ground in Africa. *Pathology Research and Practice*, **2020**, 216, 153118	3.4	1

282	IL6/STAT3 Signaling Hijacks Estrogen Receptor Enhancers to Drive Breast Cancer Metastasis. *Cancer Cell*, **2020**, 38, 412-423.e9	24.3	46
281	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. *British Journal of Cancer*, **2020**, 123, 1513-1520	8.7	3
280	Biology of Oestrogen-Receptor Positive Primary Breast Cancer in Older Women with Utilisation of Core Needle Biopsy Samples and Correlation with Clinical Outcome. *Cancers*, **2020**, 12,	6.6	2
279	Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. *Breast Cancer Research*, **2020**, 22, 85	8.3	11
278	The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. *British Journal of Cancer*, **2020**, 123, 1543-1552	8.7	8
277	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer. *JAMA Network Open*, **2020**, 3, e209486	10.4	2
276	The intra-tumoural stroma in patients with breast cancer increases with age. *Breast Cancer Research and Treatment*, **2020**, 179, 37-45	4.4	4
275	The role of glutaminase in cancer. *Histopathology*, **2020**, 76, 498-508	7.3	39
274	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 79-90	4.4	8
273	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. *Journal of Clinical Pathology*, **2020**, 73, 76-82	3.9	23
272	Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. *Metallomics*, **2019**, 11, 1579-1592	4.5	8
271	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. *Breast Cancer Research and Treatment*, **2019**, 178, 535-544	4.4	17
270	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. *British Journal of Cancer*, **2019**, 121, 776-785	8.7	7
269	Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women. *Cancers*, **2019**, 11,	6.6	7
268	The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. *Breast Cancer Research and Treatment*, **2019**, 175, 27-38	4.4	14
267	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. *Modern Pathology*, **2019**, 32, 1460-1472	9.8	13
266	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. *Modern Pathology*, **2019**, 32, 1473-1485	9.8	6
265	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. *British Journal of Cancer*, **2019**, 120, 1129-1136	8.7	12

264	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. *Artificial Intelligence in Medicine*, **2019**, 97, 27-37	7.4	18
263	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. *British Journal of Cancer*, **2019**, 120, 1075-1082	8.7	15
262	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. *Journal of Pathology*, **2019**, 248, 326-338	9.4	12
261	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. *Nature*, **2019**, 567, 399-404	50.4	108
260	Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2019**, 176, 63-73	4.4	4
259	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in□situ. *Histopathology*, **2019**, 74, 1025-1035	7.3	11
258	The role of PIP5K1/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1□inhibitor. *Oncogene*, **2019**, 38, 375-389	9.2	12
257	Machine learning-based prediction of breast cancer growth rate in vivo. *British Journal of Cancer*, **2019**, 121, 497-504	8.7	2
256	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. *Cancers*, **2019**, 11,	6.6	6
255	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. *Breast Journal*, **2019**, 25, 1143-1153	1.2	3
254	Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. *Cancers*, **2019**, 11,	6.6	27
253	A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. *Breast Cancer Research*, **2019**, 21, 83	8.3	22
252	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. *British Journal of Cancer*, **2019**, 120, 728-745	8.7	2
251	Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers. *Breast Cancer Research and Treatment*, **2019**, 175, 105-115	4.4	7
250	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. *Modern Pathology*, **2019**, 32, 967-976	9.8	17
249	Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. *Scientific Reports*, **2019**, 9, 16987	4.9	5
248	An End-to-End Deep Learning Histochemical Scoring System for Breast Cancer TMA. *IEEE Transactions on Medical Imaging*, **2019**, 38, 617-628	11.7	17
247	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 387-399	4.4	33

246	Connexin 43 is an independent predictor of patient outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2019**, 174, 93-102	4.4	20
245	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. *Modern Pathology*, **2019**, 32, 639-649	9.8	9
244	Glutamate dehydrogenase (GLUD1) expression in breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 79-91	4.4	16
243	Expression of Lamin A/C in early-stage breast cancer and its prognostic value. *Breast Cancer Research and Treatment*, **2019**, 174, 661-668	4.4	25
242	Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. *Breast Cancer Research and Treatment*, **2019**, 173, 93-102	4.4	12
241	Immune Infiltration in Invasive Lobular Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 768-776	9.7	55
240	Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. *Histopathology*, **2018**, 73, 545-558	7.3	12
239	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. *Breast Cancer Research and Treatment*, **2018**, 170, 525-533	4.4	9
238	BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 3681-3691	12.9	12
237	Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. *Breast Cancer Research and Treatment*, **2018**, 169, 277-286	4.4	10
236	IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. *Cancer Immunology, Immunotherapy*, **2018**, 67, 537-549	7.4	40
235	High nuclear MSK1 is associated with longer survival in breast cancer patients. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 509-517	4.9	9
234	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. *British Journal of Cancer*, **2018**, 118, 1142-1151	8.7	6
233	The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. *British Journal of Cancer*, **2018**, 118, 1115-1122	8.7	23
232	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. *Modern Pathology*, **2018**, 31, 1226-1236	9.8	40
231	Breast cancer histologic grading using digital microscopy: concordance and outcome association. *Journal of Clinical Pathology*, **2018**, 71, 680-686	3.9	20
230	Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. *Molecular Diagnosis and Therapy*, **2018**, 22, 79-90	4.5	8
229	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. *Modern Pathology*, **2018**, 31, 1807-1815	9.8	21

228	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. *Modern Pathology*, **2018**, 31, 1675-1682	9.8	7
227	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. *Breast Cancer Research and Treatment*, **2018**, 172, 61-68	4.4	4
226	Impact of breast cancer grade discordance on prediction of outcome. *Histopathology*, **2018**, 73, 904-915	7.3	15
225	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. *Breast Cancer Research*, **2018**, 20, 21	8.3	58
224	Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. *Oncogene*, **2018**, 37, 4489-4504	9.2	57
223	Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. *Clinical Cancer Research*, **2018**, 24, 4566-4578	12.9	24
222	MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. *British Journal of Cancer*, **2018**, 118, 258-265	8.7	47
221	Invasion in breast lesions: the role of the epithelial-stroma barrier. *Histopathology*, **2018**, 72, 1075-1083	7.3	13
220	Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 306-315	6.1	37
219	Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. *Histopathology*, **2018**, 72, 183-190	7.3	33
218	Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. *Oncotarget*, **2018**, 9, 25946-25956	3.3	25
217	Prolyl-4-hydroxylase □subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). *British Journal of Cancer*, **2018**, 119, 1518-1526	8.7	21
216	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma Induces Synthetic Lethality and Chemoprevention. *Cancer Research*, **2018**, 78, 6818-6827	10.1	18
215	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. *BMC Cancer*, **2018**, 18, 1027	4.8	3
214	Treatment strategies and survival outcomes in older women with breast cancer: A comparative study between the FOCUS cohort and Nottingham cohort. *Journal of Geriatric Oncology*, **2018**, 9, 635-641	3.6	3
213	Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. *Histopathology*, **2018**, 73, 887-896	7.3	38
212	Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. *Pathology Research and Practice*, **2017**, 213, 27-33	3.4	3
211	Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. *Histopathology*, **2017**, 70, 622-631	7.3	18

210	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. *Cancer Immunology Research*, **2017**, 5, 292-299	12.5	40
209	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. *Breast Cancer Research and Treatment*, **2017**, 164, 341-348	4.4	33
208	Phenotypic characterisation of breast cancer: the role of CDC42. *Breast Cancer Research and Treatment*, **2017**, 164, 317-325	4.4	18
207	Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. *Journal of Pathology: Clinical Research*, **2017**, 3, 105-114	5.3	5
206	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. *Histopathology*, **2017**, 71, 258-268	7.3	36
205	Molecular classification of breast cancer: what the pathologist needs to know. *Pathology*, **2017**, 49, 111-119	1.9	54
204	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. *British Journal of Cancer*, **2017**, 117, 1176-1184	8.7	10
203	Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. *British Journal of Cancer*, **2017**, 117, 826-834	8.7	7
202	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, **2017**, 19, 58	8.3	100
201	Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. *Apoptosis: an International Journal on Programmed Cell Death*, **2017**, 22, 357-368	5.4	85
200	Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. *Histopathology*, **2017**, 70, 681-692	7.3	11
199	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 239-250	6.1	12
198	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. *Histopathology*, **2017**, 70, 456-465	7.3	9
197	Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome. *PLoS ONE*, **2017**, 12, e0188528	3.7	1
196	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. *Breast*, **2017**, 35, 151-156	3.6	21
195	PKC Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. *Clinical Cancer Research*, **2016**, 22, 175-86	12.9	17
194	HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. *Clinical Cancer Research*, **2016**, 22, 905-14	12.9	13
193	Rare case of type I hypersensitivity reaction to sodium hypochlorite solution in a healthcare setting. *BMJ Case Reports*, **2016**, 2016,	0.9	14

192	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. *Breast Cancer Research and Treatment*, **2016**, 159, 215-27	4.4	59
191	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. *Breast Cancer Research and Treatment*, **2016**, 159, 457-67	4.4	16
190	The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nature Communications*, **2016**, 7, 11479	17.4	779
189	RECQL4 helicase has oncogenic potential in sporadic breast cancers. *Journal of Pathology*, **2016**, 238, 495-501	9.4	29
188	Construction of tissue microarrays from core needle biopsies - a systematic literature review. *Histopathology*, **2016**, 68, 323-32	7.3	12
187	SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. *Lancet Oncology, The*, **2016** , 17, 1004-1018	21.7	65
186	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 468, 493-502	5.1	22
185	Clinical utility of reverse phase protein array for molecular classification of breast cancer. *Breast Cancer Research and Treatment*, **2016**, 155, 25-35	4.4	13
184	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. *Molecular Oncology*, **2016**, 10, 213-23	7.9	26
183	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. *Breast Cancer Research and Treatment*, **2016**, 156, 9-20	4.4	22
182	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. *British Journal of Cancer*, **2016**, 114, 917-28	8.7	64
181	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. *Carcinogenesis*, **2016**, 37, 63-71	4.6	25
180	Differing pattern of biological characteristics of early operable primary breast cancer according to age.. *Journal of Clinical Oncology*, **2016**, 34, e23272-e23272	2.2	0
179	Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23283-e23283	2.2	
178	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. *Journal of Clinical Oncology*, **2016**, 34, 1091-1091	2.2	
177	A combined HER3-EGFR score in triple-negative breast cancer: racial differences.. *Journal of Clinical Oncology*, **2016**, 34, e12560-e12560	2.2	
176	A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.. *Journal of Clinical Oncology*, **2016**, 34, 1089-1089	2.2	0
175	Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. *Frontiers in Oncology*, **2016**, 6, 145	5.3	19

174	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. *Breast Cancer Research and Treatment*, **2016**, 158, 287-95	4.4	10
173	Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. *Diagnostic Pathology*, **2016**, 11, 82	3	24
172	Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. *Breast Cancer Research and Treatment*, **2016**, 157, 65-75	4.4	17
171	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. *Journal of Pathology: Clinical Research*, **2016**, 2, 32-40	5.3	24
170	Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. *Breast Cancer Research and Treatment*, **2016**, 159, 41-53	4.4	28
169	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. *Molecular Oncology*, **2015**, 9, 115-27	7.9	35
168	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1057-65	6.1	32
167	Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. *British Journal of Cancer*, **2015**, 112, 901-11	8.7	28
166	AKT and 14-3-3 regulate Notch4 nuclear localization. *Scientific Reports*, **2015**, 5, 8782	4.9	21
165	KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. *British Journal of Cancer*, **2015**, 112, 1929-37	8.7	43
164	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. *Molecular Oncology*, **2015**, 9, 569-85	7.9	57
163	Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 511-22	4.4	17
162	Biological and clinical significance of PARP1 protein expression in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 149, 353-62	4.4	48
161	DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. *Breast Cancer Research and Treatment*, **2015**, 150, 81-90	4.4	30
160	The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. *Breast Cancer Research and Treatment*, **2015**, 150, 91-103	4.4	10
159	Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. *Breast Cancer Research and Treatment*, **2015**, 151, 325-33	4.4	20
158	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 335-46	4.4	59
157	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. *Oncogene*, **2015**, 34, 2103-14	9.2	11

156	The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. *Journal of Cancer Research and Clinical Oncology*, **2015**, 141, 505-14	4.9	4
155	Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. *Molecular Oncology*, **2015**, 9, 204-17	7.9	55
154	Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. *Oncotarget*, **2015**, 6, 41134-45	3.3	13
153	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. *Breast Cancer Research*, **2015**, 17, 59	8.3	42
152	ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. *PLoS Biology*, **2015**, 13, e1002330	9.7	44
151	FKBPL: a marker of good prognosis in breast cancer. *Oncotarget*, **2015**, 6, 12209-23	3.3	9
150	DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. *Oncotarget*, **2015**, 6, 21964-78	3.3	17
149	The pioneer factor PBX1 is a novel driver of metastatic progression in ER-positive breast cancer. *Oncotarget*, **2015**, 6, 21878-91	3.3	28
148	Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC).. *Journal of Clinical Oncology*, **2015**, 33, 1040-1040	2.2	
147	Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. *Breast Cancer Research and Treatment*, **2014**, 144, 273-85	4.4	14
146	SUMOylation proteins in breast cancer. *Breast Cancer Research and Treatment*, **2014**, 144, 519-30	4.4	26
145	Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (70 years) women: biology and clinical outcome in comparison with younger (. *Annals of Oncology*, **2014**, 25, 837-842	10.3	7
144	Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. *Breast Cancer Research and Treatment*, **2014**, 145, 339-48	4.4	44
143	C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. *Cancer*, **2014**, 120, 163-71	6.4	38
142	Prognostic significance of lymphatic invasion in lymph node-positive breast carcinoma: findings from a large case series with long-term follow-up using immunohistochemical endothelial marker. *Modern Pathology*, **2014**, 27, 1568-77	9.8	9
141	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. *Breast Cancer Research and Treatment*, **2014**, 146, 309-20	4.4	10
140	ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. *Breast Cancer Research and Treatment*, **2014**, 147, 25-37	4.4	13
139	HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. *Breast Cancer Research and Treatment*, **2014**, 145, 33-44	4.4	26

138	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. *Breast Cancer Research and Treatment*, **2014**, 145, 317-30	4.4	10
137	Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. *PLoS ONE*, **2014**, 9, e100573	3.7	20
136	PIAS expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. *Journal of Clinical Pathology*, **2014**, 67, 301-6	3.9	9
135	Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. *British Journal of Cancer*, **2014**, 110, 1688-97	8.7	68
134	Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. *Neoplasia*, **2014**, 16, 982-91	6.4	30
133	The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin *Science Signaling*, **2014**, 7, ra58	8.8	26
132	Therapeutic targeting of integrin in breast cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	89
131	Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?. *Antioxidants and Redox Signaling*, **2014**, 21, 2262-8	8.4	19
130	Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. *Breast Cancer Research and Treatment*, **2014**, 148, 455-62	4.4	18
129	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. *BMC Cancer*, **2014**, 14, 908	4.8	33
128	Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. *BMC Cancer*, **2014**, 14, 995	4.8	14
127	Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. *Oncotarget*, **2014**, 5, 12936-49	3.3	39
126	Predicting chemotherapy response in invasive breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 1084-1084	2.2	
125	Intracellular intermolecular relationships of LKB1 in breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 554-554	2.2	
124	Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. *Malaysian Journal of Pathology*, **2014**, 36, 3-17	1.7	5
123	A quantifier-based fuzzy classification system for breast cancer patients. *Artificial Intelligence in Medicine*, **2013**, 58, 175-84	7.4	18
122	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. *British Journal of Cancer*, **2013**, 109, 1886-94	8.7	34
121	Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. *Human Pathology*, **2013**, 44, 1638-47	3.7	30

120	Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 139, 301-10	4.4	46
119	Lack of expression of the proteins GMPR2 and PPAR□are associated with the basal phenotype and patient outcome in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 137, 127-37	4.4	15
118	The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 139-53	4.4	17
117	Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 721-31	4.4	13
116	Expression of angiogenic chemokines in ovarian clear cell carcinoma. *Journal of Obstetrics and Gynaecology Research*, **2013**, 39, 297-304	1.9	4
115	Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. *British Journal of Cancer*, **2013**, 108, 1042-51	8.7	49
114	Guidelines and considerations for conducting experiments using tissue microarrays. *Histopathology*, **2013**, 62, 827-39	7.3	50
113	Characteristics of basal cytokeratin expression in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 139, 23-37	4.4	28
112	The shaping and functional consequences of the microRNA landscape in breast cancer. *Nature*, **2013**, 497, 378-82	50.4	321
111	Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. *Histopathology*, **2013**, 62, 695-701	7.3	23
110	SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy. *Cancer Research*, **2013**, 73, 6951-62	10.1	5
109	Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 90-3	1.9	2
108	Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. *ISRN Oncology*, **2013**, 2013, 675051		11
107	Abstract B046: Therapeutic targeting of integrin □6 in high-risk breast cancer **2013**,		3
106	Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (□0 years) women: Biology and clinical outcome in comparison with younger (. *Journal of Clinical Oncology*, **2013**, 31, e11608-e11608	2.2	
105	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. *Breast Cancer Research*, **2012**, 14, R3	8.3	94
104	Loss of Dicer expression is associated with breast cancer progression and recurrence. *Breast Cancer Research and Treatment*, **2012**, 135, 403-13	4.4	69
103	Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. *Breast Cancer Research and Treatment*, **2012**, 135, 555-69	4.4	38

102	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. *Breast Cancer Research and Treatment*, **2012**, 136, 419-27	4.4	20
101	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature*, **2012**, 481, 389-93	50.4	1011
100	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *Journal of Pathology*, **2012**, 227, 29-41	9.4	44
99	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **2012**, 486, 346-52	50.4	3479
98	Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. *Breast Cancer Research and Treatment*, **2012**, 134, 519-29	4.4	20
97	The prognostic significance of B lymphocytes in invasive carcinoma of the breast. *Breast Cancer Research and Treatment*, **2012**, 132, 545-53	4.4	181
96	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. *Breast Cancer Research and Treatment*, **2012**, 132, 537-44	4.4	29
95	EpCAM expression is an indicator of recurrence in basal-like breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 575-82	4.4	20
94	A CD44?/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 979-95	4.4	79
93	Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. *Breast Cancer Research and Treatment*, **2012**, 134, 171-80	4.4	16
92	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. *Histopathology*, **2012**, 60, 854-63	7.3	18
91	Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. *Journal of Clinical Pathology*, **2012**, 65, 710-4	3.9	33
90	Calpain system protein expression in basal-like and triple-negative invasive breast cancer. *Annals of Oncology*, **2012**, 23, 2289-2296	10.3	49
89	CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?. *OncoImmunology*, **2012**, 1, 364-365	7.2	33
88	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *British Journal of Cancer*, **2012**, 107, 800-7	8.7	130
87	Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic. *Annals of Oncology*, **2012**, 23, 1465-71	10.3	20
86	A study of sperm-associated antigen 5 (SPAG5) in predicting response to anthracycline (ATC)/platinum chemotherapies (CT) in breast (BC) and ovarian cancers (OVC).. *Journal of Clinical Oncology*, **2012**, 30, 1098-1098	2.2	
85	HAGE (DDX43) protein expression as an independent biomarker of poor clinical outcome of breast cancer (BC) and potential as a therapeutic target for ER-negative BC.. *Journal of Clinical Oncology*, **2012**, 30, 1013-1013	2.2	1

84	Targeting XRCC1 (X-ray repair cross-complementing gene 1) deficiency in tumors for personalized cancer therapy.. *Journal of Clinical Oncology*, **2012**, 30, 1014-1014	2.2	
83	Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues. *Methods in Molecular Biology*, **2011**, 755, 119-42	1.4	3
82	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 1949-55	2.2	961
81	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. *Nature Medicine*, **2011**, 17, 715-9	50.5	101
80	Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre. *British Journal of Cancer*, **2011**, 104, 1393-400	8.7	35
79	Calpastatin is associated with lymphovascular invasion in breast cancer. *Breast*, **2011**, 20, 413-8	3.6	24
78	Biological and clinical implications of nicastrin expression in invasive breast cancer. *Breast Cancer Research and Treatment*, **2011**, 125, 43-53	4.4	23
77	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis. *Breast Cancer Research and Treatment*, **2011**, 126, 47-54	4.4	37
76	An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 99-108	4.4	129
75	Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 407-16	4.4	45
74	Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. *Breast Cancer Research and Treatment*, **2011**, 127, 639-48	4.4	27
73	MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. *Breast Cancer Research and Treatment*, **2011**, 127, 591-9	4.4	82
72	RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. *Breast Cancer Research and Treatment*, **2011**, 128, 315-26	4.4	33
71	FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 11-21	4.4	59
70	Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. *Breast Cancer Research and Treatment*, **2011**, 130, 457-63	4.4	70
69	The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2011**, 459, 21-9	5.1	28
68	Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. *Journal of Pathology*, **2011**, 223, 358-65	9.4	63
67	Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. *International Journal of Cancer*, **2011**, 129, 1773-80	7.5	29

66	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 4273-8	2.2	549
65	p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. *Japanese Journal of Clinical Oncology*, **2011**, 41, 172-9	2.8	49
64	Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. *Modern Pathology*, **2011**, 24, 774-85	9.8	84
63	Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. *Journal of Clinical Pathology*, **2011**, 64, 995-1000	3.9	34
62	Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. *Histopathology*, **2010**, 56, 560-72	7.3	52
61	Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. *Histopathology*, **2010**, 57, 212-9	7.3	32
60	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *British Journal of Cancer*, **2010**, 103, 668-75	8.7	218
59	Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. *Histopathology*, **2010**, 56, 472-80	7.3	67
58	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616
57	Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer. *Cancer Letters*, **2010**, 289, 71-80	9.9	59
56	Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. *American Journal of Surgical Pathology*, **2010**, 34, 1472-9	6.7	110
55	Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. *Breast Cancer Research and Treatment*, **2010**, 119, 283-93	4.4	155
54	A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. *Breast Cancer Research and Treatment*, **2010**, 120, 83-93	4.4	47
53	The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. *Breast Cancer Research and Treatment*, **2010**, 120, 603-12	4.4	66
52	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. *Breast Cancer Research and Treatment*, **2010**, 121, 41-51	4.4	43
51	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. *Breast Cancer Research and Treatment*, **2010**, 122, 45-53	4.4	63
50	Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. *International Journal of Cancer*, **2010**, 126, 1761-9	7.5	29
49	A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. *Computers in Biology and Medicine*, **2010**, 40, 318-30	7	42

48	The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. *Journal of Pathology*, **2010**, 220, 419-34	9.4	49
47	Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. *Journal of Pathology*, **2010**, 222, 388-99	9.4	34
46	Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival. *Oncotarget*, **2010**, 1, 628-638	3.3	332
45	Influence of E-cadherin expression on the mammographic appearance of invasive nonlobular breast carcinoma detected at screening. *Radiology*, **2009**, 253, 51-5	20.5	11
44	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. *Cancer Research*, **2009**, 69, 3802-9	10.1	340
43	Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. *Critical Reviews in Oncology/Hematology*, **2009**, 72, 76-82	7	9
42	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. *Breast Cancer Research and Treatment*, **2009**, 117, 199-204	4.4	69
41	Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. *Breast Cancer Research and Treatment*, **2009**, 113, 59-66	4.4	42
40	The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. *Histopathology*, **2009**, 54, 419-27	7.3	9
39	Sonographic correlations with the new molecular classification of invasive breast cancer. *European Radiology*, **2009**, 19, 2342-8	8	48
38	Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. *Breast Cancer Research*, **2009**, 11, R90	8.3	37
37	Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. *Breast Cancer Research*, **2009**, 11, R60	8.3	109
36	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clinical Cancer Research*, **2009**, 15, 2302-10	12.9	371
35	Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. *British Journal of Cancer*, **2008**, 99, 327-34	8.7	122
34	Expression of BRCA1 protein in breast cancer and its prognostic significance. *Human Pathology*, **2008**, 39, 857-65	3.7	115
33	Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. *European Journal of Cancer*, **2008**, 44, 73-83	7.5	164
32	The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. *Clinical Radiology*, **2008**, 63, 1228-35	2.9	22
31	Breast carcinoma with basal phenotype: mammographic findings. *American Journal of Roentgenology*, **2008**, 191, 346-51	5.4	36

30	Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. *Clinical Cancer Research*, **2008**, 14, 6625-33	12.9	12
29	Clinical importance of estrogen receptor beta isoforms in breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 5825; author reply 5825-6	2.2	7
28	Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. *Clinical Cancer Research*, **2008**, 14, 5228-35	12.9	187
27	Assessing agreement between multiple raters with missing rating information, applied to breast cancer tumour grading. *PLoS ONE*, **2008**, 3, e2925	3.7	14
26	CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. *Breast Cancer Research and Treatment*, **2008**, 109, 325-35	4.4	110
25	The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. *Breast Cancer Research and Treatment*, **2008**, 110, 427-37	4.4	49
24	Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. *Breast Cancer Research and Treatment*, **2008**, 111, 121-7	4.4	96
23	Cluster-based visualisation with scatter matrices. *Pattern Recognition Letters*, **2008**, 29, 1814-1823	4.7	22
22	Prognostic markers in triple-negative breast cancer. *Cancer*, **2007**, 109, 25-32	6.4	963
21	A gene-expression signature to predict survival in breast cancer across independent data sets. *Oncogene*, **2007**, 26, 1507-16	9.2	191
20	Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. *British Journal of Cancer*, **2007**, 96, 1092-100	8.7	153
19	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. *Histopathology*, **2007**, 50, 434-8	7.3	132
18	The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. *Cancer Research*, **2007**, 67, 10230-40	10.1	68
17	Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. *Journal of Clinical Oncology*, **2007**, 25, 4772-8	2.2	213
16	Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. *Journal of Medical Screening*, **2007**, 14, 210-4	1.4	21
15	Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. *American Journal of Surgical Pathology*, **2007**, 31, 1825-33	6.7	142
14	FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. *Breast Cancer Research*, **2007**, 9, R23	8.3	211
13	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. *Genome Biology*, **2007**, 8, R215	18.3	230

12	MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biology*, **2007**, 8, R214	18.3	742
11	Chromosome 16 tumor-suppressor genes in breast cancer. *Genes Chromosomes and Cancer*, **2006**, 45, 527-35	5	69
10	Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. *International Journal of Cancer*, **2006**, 118, 1445-52	7.5	112
9	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. *European Journal of Cancer*, **2006**, 42, 3149-56	7.5	164
8	Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. *Modern Pathology*, **2005**, 18, 1295-304	9.8	257
7	Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. *Experimental and Toxicologic Pathology*, **2005**, 56, 255-63		43
6	NapA protects Helicobacter pylori from oxidative stress damage, and its production is influenced by the ferric uptake regulator. *Journal of Medical Microbiology*, **2003**, 52, 461-469	3.2	84
5	Adenomyosis--a result of disordered stromal differentiation. *American Journal of Pathology*, **2001**, 159, 623-30	5.8	99
4	Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. *Journal of Steroid Biochemistry and Molecular Biology*, **1998**, 67, 267-74	5.1	55
3	Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. *International Journal of Cancer*, **1997**, 72, 937-41	7.5	105
2	A comparative study of cytokine gene transcripts in normal and malignant breast tissue and primary cell cultures derived from the same tissue samples. *International Journal of Cancer*, **1996**, 66, 551-6	7.5	17
1	Interleukin-3: a putative protective factor against breast cancer which is secreted by male but not female breast fibroblasts. *International Journal of Cancer*, **1995**, 61, 416-9	7.5	6